ZURICH, Oct 25 (Reuters) - Swiss drugmaker Roche said on Sunday its experimental lung cancer drug divarasib reduced the risk ...

And divarasib reduced the risk for death by 44% during the trial, with a median overall survival (OS) of 17.7 versus 12 ...

In a Phase 3 trial of previously treated KRAS G12C-mutated non-small cell lung cancer, Roche’s investigational drug divarasib ...

A drug from Amgen could give patients with an aggressive form of lung cancer significantly more time to live when added to an ...

Nashville advocates say increasing lung cancer screening and awareness could catch the disease earlier, when patients have ...

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to durvalumab maintenance ...

Bristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trial ...

The investigational KRAS G12C inhibitor prolongs overall survival in previously treated advanced lung cancer vs existing ...

AstraZeneca (AZN) said Saturday two phase 3 trials showed its cancer drug Imfinzi helped patients with extensive-stage small cell lung cancer and muscle-invasive bladder cancer, cutting the risk of ...

Discover CHEST 2026 findings on CT phenotyping, TAPSE/sPAP risk scores, artesunate, telomere length and inhaled nintedanib in ...

Women make up more than half the population, and their heart health must be a part of everyday care across medicine,’ said Dr ...

Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI® (durvalumab) reduced the risk of death by 58% ...